Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA <i>EGFR+</i> NSCLC (Except with <i>RB</i> Alterations?) When Adopting Adjuvant Osimertinib.

Zhang, Shannon S; Ou, Sai-Hong Ignatius

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib.

Zhang, Shannon S; Ou, Sai-Hong Ignatius.

Affiliation

Zhang SS; University of California Irvine School of Medicine, Department of Medicine, Orange, CA, USA.
Ou SI; University of California Irvine School of Medicine, Department of Medicine, Orange, CA, USA.

Lung Cancer (Auckl) ; 13: 23-31, 2022.

Article in En | MEDLINE | ID: mdl-35506019

Key words

ADAURA; EGFR mutation; adjuvant; cisplatin; disease-free survival; osimertinib; platinum-based chemotherapy; resected NSCLC

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Lung Cancer (Auckl) Year: 2022 Document type: Article Affiliation country: United States Country of publication: New Zealand

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google